Brian Abrahams
Stock Analyst at RBC Capital
(3.77)
# 850
Out of 4,413 analysts
311
Total ratings
49.15%
Success rate
7.13%
Average return
Main Sectors:
29 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Sector Perform | $26 → $15 | $13.94 | +7.60% | 17 | Apr 26, 2024 | |
| GILD Gilead Sciences | Maintains: Sector Perform | $76 → $74 | $65.20 | +13.50% | 18 | Apr 26, 2024 | |
| MRNS Marinus Pharmaceuticals | Downgrades: Sector Perform | $24 → $3 | $1.41 | +112.77% | 7 | Apr 15, 2024 | |
| APLT Applied Therapeutics | Reiterates: Outperform | $12 | $4.42 | +171.49% | 2 | Apr 11, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Outperform | $1,189 | $890.66 | +33.50% | 18 | Apr 9, 2024 | |
| ITCI Intra-Cellular Therapies | Reiterates: Outperform | $86 | $71.81 | +19.76% | 13 | Apr 3, 2024 | |
| NMRA Neumora Therapeutics | Reiterates: Outperform | $31 | $9.09 | +241.03% | 3 | Mar 28, 2024 | |
| INCY Incyte | Reiterates: Sector Perform | $65 | $52.05 | +24.88% | 12 | Mar 25, 2024 | |
| HOOK HOOKIPA Pharma | Reiterates: Outperform | $5 | $0.89 | +463.51% | 7 | Mar 25, 2024 | |
| PTCT PTC Therapeutics | Reiterates: Sector Perform | $28 | $32.15 | -12.91% | 13 | Mar 8, 2024 | |
| IGMS IGM Biosciences | Reiterates: Outperform | $21 | $9.63 | +118.07% | 11 | Mar 8, 2024 | |
| MNMD Mind Medicine (MindMed) | Maintains: Outperform | $15 → $22 | $9.52 | +131.09% | 8 | Mar 8, 2024 | |
| PLRX Pliant Therapeutics | Maintains: Outperform | $50 → $54 | $11.82 | +356.85% | 10 | Mar 5, 2024 | |
| BIIB Biogen | Reiterates: Outperform | $364 | $214.82 | +69.44% | 24 | Mar 5, 2024 | |
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $56 → $55 | $40.65 | +35.30% | 11 | Mar 1, 2024 | |
| ETNB 89bio | Maintains: Sector Perform | $15 → $14 | $8.51 | +64.51% | 12 | Mar 1, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $151 → $157 | $126.66 | +23.95% | 18 | Feb 29, 2024 | |
| PRTA Prothena Corporation | Maintains: Sector Perform | $36 → $35 | $20.34 | +72.07% | 7 | Feb 16, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $397 → $420 | $392.81 | +6.92% | 40 | Feb 6, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Sector Perform | $128 → $121 | $137.54 | -12.03% | 11 | Nov 10, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $4 → $3 | $1.03 | +191.26% | 7 | Nov 3, 2023 | |
| ENTA Enanta Pharmaceuticals | Maintains: Sector Perform | $25 → $15 | $13.74 | +9.17% | 14 | Oct 2, 2023 | |
| BCRX BioCryst Pharmaceuticals | Reiterates: Outperform | $10 | $4.13 | +142.13% | 9 | Sep 25, 2023 | |
| GLPG Galapagos NV | Maintains: Sector Perform | $43 → $41 | $28.45 | +44.11% | 9 | May 8, 2023 | |
| ATAI Atai Life Sciences | Maintains: Sector Perform | $12 → $9 | $1.98 | +354.55% | 3 | Mar 31, 2022 | |
| MRUS Merus | Maintains: Sector Perform | n/a | $44.91 | - | 3 | Nov 3, 2021 | |
| CRBP Corbus Pharmaceuticals Holdings | Downgrades: Sector Perform | n/a | $37.04 | - | 1 | Sep 8, 2020 | |
| NBSE NeuBase Therapeutics | Initiates: Outperform | n/a | $0.42 | - | 1 | Jun 16, 2020 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Buy | n/a | $42.54 | - | 2 | Dec 4, 2017 |
Sage Therapeutics
Apr 26, 2024
Maintains: Sector Perform
Price Target: $26 → $15
Current: $13.94
Upside: +7.60%
Gilead Sciences
Apr 26, 2024
Maintains: Sector Perform
Price Target: $76 → $74
Current: $65.20
Upside: +13.50%
Marinus Pharmaceuticals
Apr 15, 2024
Downgrades: Sector Perform
Price Target: $24 → $3
Current: $1.41
Upside: +112.77%
Applied Therapeutics
Apr 11, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.42
Upside: +171.49%
Regeneron Pharmaceuticals
Apr 9, 2024
Reiterates: Outperform
Price Target: $1,189
Current: $890.66
Upside: +33.50%
Intra-Cellular Therapies
Apr 3, 2024
Reiterates: Outperform
Price Target: $86
Current: $71.81
Upside: +19.76%
Neumora Therapeutics
Mar 28, 2024
Reiterates: Outperform
Price Target: $31
Current: $9.09
Upside: +241.03%
Incyte
Mar 25, 2024
Reiterates: Sector Perform
Price Target: $65
Current: $52.05
Upside: +24.88%
HOOKIPA Pharma
Mar 25, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.89
Upside: +463.51%
PTC Therapeutics
Mar 8, 2024
Reiterates: Sector Perform
Price Target: $28
Current: $32.15
Upside: -12.91%
IGM Biosciences
Mar 8, 2024
Reiterates: Outperform
Price Target: $21
Current: $9.63
Upside: +118.07%
Mind Medicine (MindMed)
Mar 8, 2024
Maintains: Outperform
Price Target: $15 → $22
Current: $9.52
Upside: +131.09%
Pliant Therapeutics
Mar 5, 2024
Maintains: Outperform
Price Target: $50 → $54
Current: $11.82
Upside: +356.85%
Biogen
Mar 5, 2024
Reiterates: Outperform
Price Target: $364
Current: $214.82
Upside: +69.44%
Xenon Pharmaceuticals
Mar 1, 2024
Maintains: Outperform
Price Target: $56 → $55
Current: $40.65
Upside: +35.30%
89bio
Mar 1, 2024
Maintains: Sector Perform
Price Target: $15 → $14
Current: $8.51
Upside: +64.51%
Sarepta Therapeutics
Feb 29, 2024
Maintains: Outperform
Price Target: $151 → $157
Current: $126.66
Upside: +23.95%
Prothena Corporation
Feb 16, 2024
Maintains: Sector Perform
Price Target: $36 → $35
Current: $20.34
Upside: +72.07%
Vertex Pharmaceuticals
Feb 6, 2024
Maintains: Sector Perform
Price Target: $397 → $420
Current: $392.81
Upside: +6.92%
Neurocrine Biosciences
Nov 10, 2023
Maintains: Sector Perform
Price Target: $128 → $121
Current: $137.54
Upside: -12.03%
Karyopharm Therapeutics
Nov 3, 2023
Maintains: Outperform
Price Target: $4 → $3
Current: $1.03
Upside: +191.26%
Enanta Pharmaceuticals
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $13.74
Upside: +9.17%
BioCryst Pharmaceuticals
Sep 25, 2023
Reiterates: Outperform
Price Target: $10
Current: $4.13
Upside: +142.13%
Galapagos NV
May 8, 2023
Maintains: Sector Perform
Price Target: $43 → $41
Current: $28.45
Upside: +44.11%
Atai Life Sciences
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $1.98
Upside: +354.55%
Merus
Nov 3, 2021
Maintains: Sector Perform
Price Target: n/a
Current: $44.91
Upside: -
Corbus Pharmaceuticals Holdings
Sep 8, 2020
Downgrades: Sector Perform
Price Target: n/a
Current: $37.04
Upside: -
NeuBase Therapeutics
Jun 16, 2020
Initiates: Outperform
Price Target: n/a
Current: $0.42
Upside: -
Ultragenyx Pharmaceutical
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $42.54
Upside: -